|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort显示文摘AIM:To determine the rates and impact of hepatitis B virus(HBV) and hepatitis C virus(HCV) infections on response to long-term highly active antiretroviral therapy(HAART) in a large human immunodeficiency virus(HIV) population in Nigeria.METHODS:HBV and HCV as well as HIV infections are endemic in sub Saharan Africa.This was a retrospective cohort study of 19 408 adults who were recruited between June 2004 and December 2010 in the AIDS Prevention Initiative in Nigeria in Nigeria programme at Jos University Teaching Hospital.Serological assays,including HBV surface antigen(HBsAg) and hepatitis C antibody were used to categorise hepatitis status of the patients.HBsAg was determined using enzyme immunoassay(EIA)(Monolisa HBsAg Ultra3;Bio-Rad).HCV antibody was tested using third generation EIA(DIA.PRO Diagnostic,Bioprobes srl,Milan,Italy).HIV RNA levels were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5(Roche Diagnostics,GmbH,Mannheim,Germany) with a detection limit of 400 copies/mL.Flow cytometry was used to determine CD4+ cell count(Partec,GmbH Munster,Germany).Comparison of categorical and continuous variables were achieved using Pearson's χ 2 and Kruskal Wallis tests respectively,on MedCalc for Windows,version 9.5.0.0(MedCalc Software,Mariakerke,Belgium).RESULTS:With an overall hepatitis screening rate of over 90% for each virus;HBV,HCV and HBV/HCV were detected in 3162(17.8%),1983(11.3%) and 453(2.5%) HIV infected adults respectively.The rate of liver disease was low,but highest among HIV monoinfected patients(29,0.11%),followed by HBV coinfected patients(15,0.08%).Patients with HBV coinfection and triple infection had higher log 10 HIV RNA loads(HBV:4.6 copies/mL vs HIV only:4.5 copies/mL,P<0.0001) and more severe immune suppression(HBV:645,55.4%;HBV/HCV:97,56.7%) prior to initiation of HAART compared to HIV mono-infected patients(1852,48.6%)(P<0.0001).Of 3025 patients who were 4.4 years on HAART and whose CD4 cell counts results at baseline and end of follow up were available for analyses,CD4 increase was significantly lower in those with HBV co-infection(HBV:144 cells/mm3 ;HBV/HCV:105 cells/mm3) than in those with HCV co-infection(165 cells/mm3) and HIV mono-infection(150 cells/mm3)(P=0.0008).CONCLUSION:High rates of HBV and HCV infections were found in this HIV cohort.CD4 recovery was significantly diminished in patients with HBV co-infection. | Nimzing Gwamzhi Ladep Patricia Aladi Agaba Oche Agbaji Auwal Muazu Placid Ugoagwu Godwin Imade Graham Cooke Sheena McCormack Simon David Taylor-Robinson John Idoko Phyllis Kanki | 2013 | World Journal of Gastroenterology2013，19，10： | 3 |
| 2 | Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study显示文摘 | Danielle Ní Chróinín Elizabeth L. Callaly Joseph Duggan áine Merwick Niamh Hannon órla Sheehan Michael Marnane Gillian Horgan Emma B. Williams Dawn Harris Lorraine Kyne Patricia M.E. McCormack Joan Moroney Tim Grant David Williams Leslie Daly Peter J. Kel | 2011 | Stroke2011，，： | 1 |
| 3 | Pulmonary oxidant stress in murine sepsis is due to inflammatory cell nitric oxide显示文摘 | Habib M. Razavi Lefeng Wang Sean Weicker Greg J. Quinlan Sharon Mumby David G. McCormack Sanjay Mehta | 2005 | Critical Care Medicine2005，，6： | 1 |
| 4 | Pterostilbene and Cancer: Current Review显示文摘 | Denise McCormack David McFadden | 2012 | Journal of Surgical Research2012，，2： | 1 |
| 5 | Hyperpolarized 3 He Magnetic Resonance Functional Imaging Semiautomated Segmentation显示文摘 | Miranda Kirby Mohammadreza Heydarian Sarah Svenningsen Andrew Wheatley David G. McCormack Roya Etemad-Rezai Grace Parraga | 2012 | Academic Radiology2012，，： | 1 |
| 6 | Temperatures in deep grinding of finite workpieces 显示文摘 | Tan Jin W Brian Rowe David McCormack | 2002 | International Journal of Machine Tools & Manufacture (S0890-6955)2002，42，1： | 1 |
| 7 | Undiagnosed sleep apnoea syndrome in patients with acute myocardial infarction: Potential importance of the STOP-BANG screening tool for clinical practice显示文摘 | David J. McCormack Ravinder Pabla Mohammed Hilal Babu Linda Dykes Philip Dale R. Andrew Archbold Margaret Pilling Amy Clifford Francesca Cormack Alex Shipolini Alexandra M. Hogan | 2011 | International Journal of Cardiology2011，，2： | 1 |
| 8 | Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study显示文摘 | Danielle Ní Chróinín Elizabeth L. Callaly Joseph Duggan áine Merwick Niamh Hannon órla Sheehan Michael Marnane Gillian Horgan Emma B. Williams Dawn Harris Lorraine Kyne Patricia M.E. McCormack Joan Moroney Tim Grant David Williams Leslie Daly Peter J. Kel | 2011 | Stroke2011，，4： | 1 |
| 9 | Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease显示文摘AIM To evaluate a calcium activated potassium channel(KCa3.1) inhibitor attenuates liver disease in models of non-alcoholic fatty liver disease(NAFLD).METHODS We have performed a series of in vitro and in vivo studies using the KCa3.1 channel inhibitor, Senicapoc. Efficacy studies of Senicapoc were conducted in toxin-, thioacetamide(TAA) and high fat diet(HFD)-induced models of liver fibrosis in rats. Efficacy and pharmacodynamic effects of Senicapoc was determined through biomarkers of apoptosis, inflammation, steatosis and fibrosis. RESULTS Upregulation of KCa3.1 expression was recorded in TAA-induced and high fat diet-induced liver disease. Treatment with Senicapoc decreased palmitic aciddriven Hep G2 cell death.(P < 0.05 vs control) supporting the finding that Senicapoc reduces lipiddriven apoptosis in Hep G2 cell cultures. In animals fed a HFD for 6 wk, co-treatment with Senicapoc,(1) reduced non-alcoholic fatty liver disease(NAFLD) activity score(NAS)(0-8 scale),(2) decreased steatosis and(3) decreased hepatic lipid content(Oil Red O, P < 0.05 vs vehicle). Randomization of TAA animals and HFD fed animals to Senicapoc was associated with a decrease in liver fibrosis as evidenced by hydroxyproline and Masson's trichrome staining(P < 0.05 vs vehicle). These results demonstrated that Senicapoc mitigates both steatosis and fibrosis in liver fibrosis models.CONCLUSION These data suggest that Senicapoc interrupts more than one node in progressive fatty liver disease by its anti-steatotic and anti-fibrotic activities, serving as a double-edged therapeutic sword. | latha paka david e smith dawoon jung siobhan mccormack ping zhou bin duan jing-song li jiaqi shi yong-jie hao kai jiang michael yamin itzhak d goldberg prakash narayan | 2017 | World Journal of Gastroenterology2017，23，23： | 1 |
| 10 | Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial显示文摘 | R Paul Symonds Charlie Gourley Susan Davidson Karen Carty Elaine McCartney Debbie Rai Susana Banerjee David Jackson Rosemary Lord Mary McCormack Emma Hudson Nicholas Reed Maxine Flubacher Petra Jankowska Melanie Powell Caroline Dive Catharine M L West Jam | 2015 | The Lancet Oncology2015，，15： | 1 |
| 11 | Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease显示文摘Biologic agents have now been used in the management of inflammatory bowel disease(IBD)for many years where experience,expertise and confidence in their use has developed over time.In the United Kingdom,there are well established guidelines and recommendations for both single agent biologic treatments,and with combination therapy of a biologic agent with a small molecule agent in maintenance therapy.In recent times,there has been increasing interest and experience using dual biologic therapy(DBT)in IBD,primarily in difficult to treat and refractory cases with high disease burden.However,published data on use,experience and safety profiles is limited and large-scale studies remain low in number in this developing area.We therefore aim to present a summary and review of the available published data in this area to help us better understand the emerging role of DBT in IBD. | Matthew D McCormack Natasha A Wahedna David Aldulaimi Peter Hawker | 2023 | World Journal of Clinical Cases2023，11，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员